Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and represents a high-grade neoplasm of skeletal myoblast-like cells. Decades of clinical and basic research have gradually improved our understanding of the pathophysiology of RMS and helped to optimize clinical care. The two major subtypes of RMS, originally characterized on the basis of light microscopic features, are driven by fundamentally different molecular mechanisms and pose distinct clinical challenges. Curative therapy depends on control of the primary tumour, which can arise at many distinct anatomical sites, as well as controlling disseminated disease that is known or assumed to be present in every case. Sophisticated risk stratification for children with RMS incorporates various clinical, pathological and molecular features, and that information is used to guide the application of multifaceted therapy. Such therapy has historically included cytotoxic chemotherapy as well as surgery, ionizing radiation or both. This Primer describes our current understanding of RMS epidemiology, disease susceptibility factors, disease mechanisms and elements of clinical care, including diagnostics, risk-based care of newly diagnosed and relapsed disease and the prevention and management of late effects in survivors. We also outline potential opportunities to further translate new biological insights into improved clinical outcomes.
This is a preview of subscription content
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $59.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Hawkins, D. S., Spunt, S. L. & Skapek, S. X. Children’s Oncology Group’s 2013 blueprint for research: soft tissue sarcomas. Pediatr. Blood Cancer 60, 1001–1008 (2013).
Crist, W. M. et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J. Clin. Oncol. 19, 3091–3102 (2001).
Crist, W. et al. The third intergroup rhabdomyosarcoma study. J. Clin. Oncol. 13, 610–630 (1995).
Raney, R. B. et al. The intergroup rhabdomyosarcoma study group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma 5, 9–15 (2001).
Arndt, C. A. et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children’s oncology group study D9803. J. Clin. Oncol. 27, 5182–5188 (2009).
Stevens, M. C. et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology—SIOP Malignant Mesenchymal Tumor 89. J. Clin. Oncol. 23, 2618–2628 (2005).
Oberlin, O. et al. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. J. Clin. Oncol. 30, 2457–2465 (2012).
Enterline, H. T. & Horn, R. C. Jr. Alveolar rhabdomyosarcoma; a distinctive tumor type. Am. J. Clin. Pathol. 29, 356–366 (1958).
Patton, R. B. & Horn, R. C. Jr. Rhabdomyosarcoma: clinical and pathological features and comparison with human fetal and embryonal skeletal muscle. Surgery 52, 572–584 (1962).
Turc-Carel, C. et al. Consistent chromosomal translocation in alveolar rhabdomyosarcoma. Cancer Genet. Cytogenet. 19, 361–362 (1986).
Douglass, E. C. et al. Variant translocations of chromosome 13 in alveolar rhabdomyosarcoma. Genes Chromosomes Cancer 3, 480–482 (1991).
Douglass, E. C. et al. A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet. Cell Genet. 45, 148–155 (1987).
Rudzinski, E. R. et al. The World Health Organization classification of skeletal muscle tumors in pediatric rhabdomyosarcoma: a report from the Children’s Oncology Group. Arch. Pathol. Lab. Med. 139, 1281–1287 (2015).
Barr, F. G. et al. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat. Genet. 3, 113–117 (1993).
Davis, R. J., D’Cruz, C. M., Lovell, M. A., Biegel, J. A. & Barr, F. G. Fusion of PAX7 to FKHR by the variant t(1;13)(p36; q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 54, 2869–2872 (1994).
Parham, D. M. & Barr, F. G. Classification of rhabdomyosarcoma and its molecular basis. Adv. Anat. Pathol. 20, 387–397 (2013).
Ries, L. A. G. et al. (eds) Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1999 [pub no. 99-4649] (National Cancer Institute, 1999).
Perez, E. A. et al. Rhabdomyosarcoma in children: a SEER population based study. J. Surg. Res. 170, e243–e251 (2011).
Lychou, S. E., Gustafsson, G. G. & Ljungman, G. E. Higher rates of metastatic disease may explain the declining trend in Swedish paediatric rhabdomyosarcoma survival rates. Acta Paediatr. 105, 74–81 (2016).
Stiller, C. A. & Parkin, D. M. International variations in the incidence of childhood soft-tissue sarcomas. Paediatr. Perinat. Epidemiol. 8, 107–119 (1994).
Ognjanovic, S., Linabery, A. M., Charbonneau, B. & Ross, J. A. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975–2005. Cancer 115, 4218–4226 (2009). This paper demonstrates increasing incidence of RMS in the United States.
Kelly, K. M., Womer, R. B., Sorensen, P. H., Xiong, Q. B. & Barr, F. G. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J. Clin. Oncol. 15, 1831–1836 (1997).
Furlong, M. A., Mentzel, T. & Fanburg-Smith, J. C. Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers. Mod. Pathol. 14, 595–603 (2001).
Chow, E. J. et al. Childhood cancer in relation to parental race and ethnicity: a 5-state pooled analysis. Cancer 116, 3045–3053 (2010).
Grufferman, S., Ruymann, F., Ognjanovic, S., Erhardt, E. B. & Maurer, H. M. Prenatal X-ray exposure and rhabdomyosarcoma in children: a report from the children’s oncology group. Cancer Epidemiol. Biomarkers Prev. 18, 1271–1276 (2009).
Savage, S. A. et al. Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat. Genet. 45, 799–803 (2013).
Postel-Vinay, S. et al. Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat. Genet. 44, 323–327 (2012).
Shern, J. F. et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 4, 216–231 (2014).
Chen, X. et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 24, 710–724 (2013). References 28 and 29 represent two of the early and comprehensive applications of next-generation sequencing approaches to investigate RMS pathogenesis.
Seki, M. et al. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma. Nat. Commun. 6, 7557 (2015).
Diller, L., Sexsmith, E., Gottlieb, A., Li, F. P. & Malkin, D. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J. Clin. Invest. 95, 1606–1611 (1995).
Hartley, A. L., Birch, J. M., Marsden, H. B., Harris, M. & Blair, V. Neurofibromatosis in children with soft tissue sarcoma. Pediatr. Hematol. Oncol. 5, 7–16 (1988).
Yang, P. et al. Association of childhood rhabdomyosarcoma with neurofibromatosis type I and birth defects. Genet. Epidemiol. 12, 467–474 (1995). This paper reports the important addition of RMS to the cancer susceptibility imposed by heritable genetic defects, including NF1 mutation.
Kratz, C. P., Rapisuwon, S., Reed, H., Hasle, H. & Rosenberg, P. S. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am. J. Med. Genet. 157C, 83–89 (2011).
Estep, A. L., Tidyman, W. E., Teitell, M. A., Cotter, P. D. & Rauen, K. A. HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am. J. Med. Genet. 140A, 8–16 (2006).
Shuman, C., Beckwith, J. B. & Weksberg, R. Beckwith-Wiedemann syndrome. GeneReviews https://www.ncbi.nlm.nih.gov/books/NBK1394 (updated 11 Aug 2016).
Doros, L. et al. DICER1 mutations in embryonal rhabdomyosarcomas from children with and without familial PPB-tumor predisposition syndrome. Pediatr. Blood Cancer 59, 558–560 (2012).
Plon, S. E. & Malkin, D. in Principles and Practice of Pediatric Oncology (eds Pizzo, P. A. & Poplack, D. G.) 1600 (Lippincott Williams & Wilkins, Philadelphia, PA, 2010).
Ognjanovic, S., Olivier, M., Bergemann, T. L. & Hainaut, P. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer 118, 1387–1396 (2012).
Keller, C. et al. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev. 18, 2614–2626 (2004). This elegant study demonstrates the power of genetically engineered mouse models in the study of translocation-driven sarcomas.
Grufferman, S., Delzell, E. & Delong, E. R. An approach to conducting epidemiologic research within cooperative clinical trials groups. J. Clin. Oncol. 2, 670–675 (1984).
Grufferman, S., Schwartz, A. G., Ruymann, F. B. & Maurer, H. M. Parents’ use of cocaine and marijuana and increased risk of rhabdomyosarcoma in their children. Cancer Causes Control 4, 217–224 (1993).
Lupo, P. J. et al. Maternal and birth characteristics and childhood rhabdomyosarcoma: a report from the Children’s Oncology Group. Cancer Causes Control 25, 905–913 (2014).
Lupo, P. J. et al. Allergies, atopy, immune-related factors and childhood rhabdomyosarcoma: a report from the Children’s Oncology Group. Int. J. Cancer 134, 431–436 (2014).
Lupo, P. J. et al. Family history of cancer and childhood rhabdomyosarcoma: a report from the Children’s Oncology Group and the Utah Population Database. Cancer Med. 4, 781–790 (2015).
Ottaviani, G. & Jaffe, N. The epidemiology of osteosarcoma. Cancer Treat. Res. 152, 3–13 (2009).
Eyre, R., Feltbower, R. G., Mubwandarikwa, E., Eden, T. O. & McNally, R. J. Epidemiology of bone tumours in children and young adults. Pediatr. Blood Cancer 53, 941–952 (2009).
Grufferman, S. et al. Environmental factors in the etiology of rhabdomyosarcoma in childhood. J. Natl Cancer Inst. 68, 107–113 (1982).
Grimson, R. C., Aldrich, T. E. & Drane, J. W. Clustering in sparse data and an analysis of rhabdomyosarcoma incidence. Stat. Med. 11, 761–768 (1992).
Linardic, C. M. et al. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Res. 67, 6691–6699 (2007).
Drummond, C. J. et al. Hedgehog pathway drives fusion-negative rhabdomyosarcoma initiated from non-myogenic endothelial progenitors. Cancer Cell 33, 108–124 (2018).
Marshall, A. D. & Grosveld, G. C. Alveolar rhabdomyosarcoma — the molecular drivers of PAX3/7-FOXO1-induced tumorigenesis. Skelet. Muscle 2, 25 (2012).
Barr, F. G. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 20, 5736–5746 (2001).
Galili, N. et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat. Genet. 5, 230–235 (1993). This seminal work describes the identification of the PAX3–FOXO1 fusion transcript.
Bennicelli, J. L., Advani, S., Schafer, B. W. & Barr, F. G. PAX3 and PAX7 exhibit conserved cis -acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. Oncogene 18, 4348–4356 (1999).
Bennicelli, J. L., Edwards, R. H. & Barr, F. G. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. Proc. Natl Acad. Sci. USA 93, 5455–5459 (1996).
Davis, R. J. & Barr, F. G. Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc. Natl Acad. Sci. USA 94, 8047–8051 (1997).
del Peso, L., Gonzalez, V. M., Hernandez, R., Barr, F. G. & Nunez, G. Regulation of the forkhead transcription factor FKHR, but not the PAX3–FKHR fusion protein, by the serine/threonine kinase Akt. Oncogene 18, 7328–7333 (1999).
Thalhammer, V. et al. PLK1 phosphorylates PAX3–FOXO1, the inhibition of which triggers regression of alveolar rhabdomyosarcoma. Cancer Res. 75, 98–110 (2015).
Bharathy, N. et al. P/CAF mediates PAX3–FOXO1-dependent oncogenesis in alveolar rhabdomyosarcoma. J. Pathol. 240, 269–281 (2016).
Amstutz, R. et al. Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities. Cancer Res. 68, 3767–3776 (2008).
Cao, L. et al. Genome-wide identification of PAX3–FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res. 70, 6497–6508 (2010).
Gryder, B. E. et al. PAX3–FOXO1 establishes myogenic super enhancers and confers BET bromodomain vulnerability. Cancer Discov. 7, 884–899 (2017). References 62 and 63 provide elegant insight into how the oncogenic fusion protein derails developmental pathways to foster tumour formation and progression.
Bohm, M. et al. Helicase CHD4 is an epigenetic coregulator of PAX3–FOXO1 in alveolar rhabdomyosarcoma. J. Clin. Invest. 126, 4237–4249 (2016).
Lam, P. Y. P., Sublett, J. E., Hollenbach, A. D. & Roussel, M. F. The oncogenic potential of the Pax3–FKHR fusion protein requires the pax3 homeodomain recognition helix but not the pax3 paired-box DNA binding domain. Mol. Cell. Biol. 19, 594–601 (1999).
Xia, S. J., Holder, D. D., Pawel, B. R., Zhang, C. & Barr, F. G. High expression of the PAX3–FKHR oncoprotein is required to promote tumorigenesis of human myoblasts. Am. J. Pathol. 175, 2600–2608 (2009).
Kikuchi, K. et al. Effects of PAX3–FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem. Biophys. Res. Commun. 365, 568–574 (2008).
Ebauer, M., Wachtel, M., Niggli, F. K. & Schafer, B. W. Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR. Oncogene 26, 7267–7281 (2007).
Sorensen, P. H. et al. PAX3–FKHR and PAX7–FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children’s oncology group. J. Clin. Oncol. 20, 2672–2679 (2002).
Barr, F. G. et al. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res. 62, 4704–4710 (2002).
Wachtel, M. et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res. 64, 5539–5545 (2004).
Williamson, D. et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J. Clin. Oncol. 28, 2151–2158 (2010).
Weber-Hall, S. et al. Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. Cancer Res. 56, 3220–3224 (1996).
Shukla, N. et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin. Cancer Res. 18, 748–757 (2012).
Davicioni, E. et al. Molecular classification of rhabdomyosarcoma — genotypic and phenotypic determinants of diagnosis. Am. J. Pathol. 174, 550–564 (2009).
Stewart, E. et al. Identification of therapeutic targets in rhabdomyosarcoma through integrated genomic, epigenomic, and proteomic analyses. Cancer Cell 34, 411–426 (2018).
Martinelli, S. et al. RAS signaling dysregulation in human embryonal rhabdomyosarcoma. Genes Chromosomes Cancer 48, 975–982 (2009).
Davicioni, E. et al. Identification of a PAX–FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res. 66, 6936–6946 (2006).
Tremblay, A. M. et al. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. Cancer Cell 26, 273–287 (2014).
Romualdi, C. et al. Defining the gene expression signature of rhabdomyosarcoma by meta-analysis. BMC Genomics 7, 287 (2006).
Renshaw, J. et al. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. Clin. Cancer Res. 19, 5940–5951 (2013).
Taylor, J. G. et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J. Clin. Invest. 119, 3395–3407 (2009). This elegant report highlights FGFR4 as one of the relative few, targetable vulnerabilities in RMS.
Li, S. Q. et al. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). PLOS ONE 8, e76551 (2013).
Crose, L. E. et al. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin. Cancer Res. 18, 3780–3790 (2012).
Wachtel, M. et al. FGFR4 signaling couples to Bim and not Bmf to discriminate subsets of alveolar rhabdomyosarcoma cells. Int. J. Cancer 135, 1543–1552 (2014).
Bridge, J. A. et al. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer 33, 310–321 (2002).
Martins, A. S., Olmos, D., Missiaglia, E. & Shipley, J. Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives. Sarcoma 2011, 209736 (2011).
Petricoin, E. F. 3rd et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 67, 3431–3440 (2007).
Wan, X., Yeung, C., Heske, C., Mendoza, A. & Helman, L. J. IGF-1R inhibition activates a YES/SFK bypass resistance pathway: rational basis for co-targeting IGF-1R and Yes/SFK kinase in rhabdomyosarcoma. Neoplasia 17, 358–366 (2015).
Ganti, R. et al. Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Mod. Pathol. 19, 1213–1220 (2006).
Mark, H. F., Brown, S., Sun, C. L., Samy, M. & Afify, A. Fluorescent in situ hybridization detection of HER-2/neu gene amplification in rhabdomyosarcoma. Pathobiology 66, 59–63 (1998).
Abraham, J. et al. Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. Mol. Cancer Ther. 10, 697–707 (2011).
Blake, J. & Ziman, M. R. Aberrant PAX3 and PAX7 expression. A link to the metastatic potential of embryonal rhabdomyosarcoma and cutaneous malignant melanoma? Histol. Histopathol. 18, 529–539 (2003).
Chiappalupi, S., Riuzzi, F., Fulle, S., Donato, R. & Sorci, G. Defective RAGE activity in embryonal rhabdomyosarcoma cells results in high PAX7 levels that sustain migration and invasiveness. Carcinogenesis 35, 2382–2392 (2014).
Megiorni, F. et al. Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells. J. Hematol. Oncol. 10, 161 (2017).
Rees, H. et al. The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas. Growth Factors 24, 197–208 (2006).
Taulli, R. et al. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res. 66, 4742–4749 (2006).
Otabe, O. et al. MET/ERK2 pathway regulates the motility of human alveolar rhabdomyosarcoma cells. Oncol. Rep. 37, 98–104 (2017).
Skrzypek, K. et al. Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression. Oncotarget 6, 31378–31398 (2015).
Miekus, K. et al. The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation. Cell Death Dis. 4, e459 (2013).
Taniguchi, E. et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 27, 6550–6560 (2008).
Ehnman, M. et al. Distinct effects of ligand-induced PDGFRalpha and PDGFRbeta signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments. Cancer Res. 73, 2139–2149 (2013).
Shern, J. F. et al. Targeted resequencing of pediatric rhabdomyosarcoma: report from the Children’s Oncology Group, The Children’s Cancer and Leukemia Group, The Institute of Cancer Research UK, and the National Cancer Institute. J. Clin. Oncol. 36, S10515 (2018).
Naini, S. et al. Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Res. 68, 9583–9588 (2008).
Hayes, M. N. & Langenau, D. M. Discovering novel oncogenic pathways and new therapies using zebrafish models of sarcoma. Methods Cell Biol. 138, 525–561 (2017).
Annavarapu, S. R. et al. Characterization of Wnt/beta-catenin signaling in rhabdomyosarcoma. Lab. Invest. 93, 1090–1099 (2013).
Chen, E. Y. et al. Glycogen synthase kinase 3 inhibitors induce the canonical WNT/beta-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma. Proc. Natl Acad. Sci. USA 111, 5349–5354 (2014).
Satheesha, S. et al. Targeting Hedgehog signaling reduces self-renewal in embryonal rhabdomyosarcoma. Oncogene 35, 2020–2030 (2016).
Zibat, A. et al. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma. Oncogene 29, 6323–6330 (2010).
Almazan-Moga, A. et al. Ligand-dependent Hedgehog pathway activation in rhabdomyosarcoma: the oncogenic role of the ligands. Br. J. Cancer 117, 1314–1325 (2017).
Conti, B., Slemmons, K. K., Rota, R. & Linardic, C. M. Recent insights into Notch signaling in embryonal rhabdomyosarcoma. Curr. Drug Targets 17, 1235–1244 (2015).
Mohamed, A. D., Tremblay, A. M., Murray, G. I. & Wackerhage, H. The Hippo signal transduction pathway in soft tissue sarcomas. Biochim. Biophys. Acta 1856, 121–129 (2015).
Crose, L. E. et al. Alveolar rhabdomyosarcoma-associated PAX3–FOXO1 promotes tumorigenesis via Hippo pathway suppression. J. Clin. Invest. 124, 285–296 (2014). This elegant study demonstrates the intersection between oncogenic fusion protein and key developmental pathways in RMS genesis.
Slemmons, K. K., Crose, L. E., Rudzinski, E., Bentley, R. C. & Linardic, C. M. Role of the YAP oncoprotein in priming Ras-driven rhabdomyosarcoma. PLOS ONE 10, e0140781 (2015).
Roma, J., Almazan-Moga, A., Sanchez de Toledo, J. & Gallego, S. Notch, Wnt, and Hedgehog pathways in rhabdomyosarcoma: from single pathways to an integrated network. Sarcoma 2012, 695603 (2012).
Kohsaka, S. et al. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K–AKT pathway mutations. Nat. Genet. 46, 595–600 (2014).
Van Antwerp, M. E., Chen, D. G., Chang, C. & Prochownik, E. V. A point mutation in the MyoD basic domain imparts c-Myc-like properties. Proc. Natl Acad. Sci. USA 89, 9010–9014 (1992).
MacQuarrie, K. L. et al. Comparison of genome-wide binding of MyoD in normal human myogenic cells and rhabdomyosarcomas identifies regional and local suppression of promyogenic transcription factors. Mol. Cell. Biol. 33, 773–784 (2013).
Lee, M. H., Jothi, M., Gudkov, A. V. & Mal, A. K. Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state. Cancer Res. 71, 3921–3931 (2011).
Walters, Z. S. et al. JARID2 is a direct target of the PAX3–FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene 33, 1148–1157 (2014).
Ciarapica, R. et al. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3–FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx). Oncogene 33, 4173–4184 (2014).
Huynh, K. D., Fischle, W., Verdin, E. & Bardwell, V. J. BCoR, a novel corepressor involved in BCL-6 repression. Genes Dev. 14, 1810–1823 (2000).
Missiaglia, E. et al. MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas. Cancer Lett. 385, 251–260 (2017).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Marshall, A. D., Lagutina, I. & Grosveld, G. C. PAX3–FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis. Cancer Res. 71, 7471–7480 (2011).
Yu, Y., Davicioni, E., Triche, T. J. & Merlino, G. The homeoprotein Six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. Cancer Res. 66, 1982–1989 (2006).
Zheng, H. & Kang, Y. Multilayer control of the EMT master regulators. Oncogene 33, 1755–1763 (2014).
Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial–mesenchymal transitions in development and disease. Cell 139, 871–890 (2009).
Skrzypek, K. et al. SNAIL is a key regulator of alveolar rhabdomyosarcoma tumor growth and differentiation through repression of MYF5 and MYOD function. Cell Death Dis. 9, 643 (2018).
Ignatius, M. S. et al. The NOTCH1/SNAIL1/MEF2C pathway regulates growth and self-renewal in embryonal rhabdomyosarcoma. Cell Rep. 19, 2304–2318 (2017).
Khan, J. et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3–FKHR fusion oncogene. Proc. Natl Acad. Sci. USA 96, 13264–13269 (1999).
Xu, L. et al. Integrative Bayesian analysis identifies rhabdomyosarcoma disease genes. Cell Rep. 24, 238–251 (2018).
Soleimani, V. D. et al. Snail regulates MyoD binding-site occupancy to direct enhancer switching and differentiation-specific transcription in myogenesis. Mol. Cell 47, 457–468 (2012).
Lopez-Soto, A., Gonzalez, S., Smyth, M. J. & Galluzzi, L. Control of metastasis by NK cells. Cancer Cell 32, 135–154 (2017).
Eichmuller, S. B., Osen, W., Mandelboim, O. & Seliger, B. Immune modulatory microRNAs involved in tumor attack and tumor immune escape. J. Natl Cancer Inst. 109, djx034 (2017).
Tran, E., Robbins, P. F. & Rosenberg, S. A. ‘Final common pathway’ of human cancer immunotherapy: targeting random somatic mutations. Nat. Immunol. 18, 255–262 (2017).
Davicioni, E., Anderson, J. R., Buckley, J. D., Meyer, W. H. & Triche, T. J. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children’s oncology group. J. Clin. Oncol. 28, 1240–1246 (2010).
Rodeberg, D. A. et al. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children’s Oncology Group. J. Clin. Oncol. 29, 1304–1311 (2011).
Mackall, C. L. et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin. Cancer Res. 14, 4850–4858 (2008).
Qualman, S. J. et al. Intergroup rhabdomyosarcoma study: update for pathologists. Pediatr. Dev. Pathol. 1, 550–561 (1998).
Oberlin, O. et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J. Clin. Oncol. 26, 2384–2389 (2008). This international effort defines new clinical features to more precisely define risk groups among children with metastatic disease.
Miser, J. S. & Pizzo, P. A. Soft tissue sarcomas in childhood. Pediatr. Clin. North Am. 32, 779–800 (1985).
Haussler, S. M. et al. Head and neck rhabdomyosarcoma in children: a 20-year retrospective study at a tertiary referral center. J. Cancer Res. Clin. Oncol. 144, 371–379 (2018).
Sachedina, A., Chan, K., MacGregor, D., Campbell, M. & Grover, S. R. More than grapes and bleeding: an updated look at pelvic rhabdomyosarcoma in young females. J. Pediatr. Adolesc. Gynecol. 31, 522–525 (2018).
Fernandez-Pineda, I. et al. Vaginal tumors in childhood: the experience of St. Jude Children’s Research Hospital. J. Pediatr. Surg. 46, 2071–2075 (2011).
Karcioglu, Z. A., Hadjistilianou, D., Rozans, M. & DeFrancesco, S. Orbital rhabdomyosarcoma. Cancer Control 11, 328–333 (2004).
Doyle, L. A. Sarcoma classification: an update based on the 2013 World Health Organization classification of tumors of soft tissue and bone. Cancer 120, 1763–1774 (2014).
Dziuba, I., Kurzawa, P., Dopierala, M., Larque, A. B. & Januszkiewicz-Lewandowska, D. Rhabdomyosarcoma in children — current pathologic and molecular classification. Pol. J. Pathol. 69, 20–32 (2018).
Parham, D. (ed.) Pediatric Neoplasia: Morphology and Biology 87–104 (Lippincott-Raven, 1996).
Rudzinski, E. R. et al. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Am. J. Clin. Pathol. 140, 82–90 (2013).
Rudzinski, E. R. Histology and fusion status in rhabdomyosarcoma. Am. Soc. Clin. Oncol. Educ. Book 2013, 425–428 (2013).
Arnold, M. A. et al. Histology, fusion status, and outcome in alveolar rhabdomyosarcoma with low-risk clinical features: a report from the Children’s Oncology Group. Pediatr. Blood Cancer 63, 634–639 (2016).
Ruiz-Mesa, C., Goldberg, J. M., Coronado Munoz, A. J., Dumont, S. N. & Trent, J. C. Rhabdomyosarcoma in adults: new perspectives on therapy. Curr. Treat. Options Oncol. 16, 27 (2015).
Noujaim, J. et al. Adult pleomorphic rhabdomyosarcoma: a multicentre retrospective study. Anticancer Res. 35, 6213–6217 (2015).
Goldstein, M., Meller, I., Issakov, J. & Orr-Urtreger, A. Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors. Neoplasia 8, 332–343 (2006).
Arnold, M. A. & Barr, F. G. Molecular diagnostics in the management of rhabdomyosarcoma. Expert Rev. Mol. Diagn. 17, 189–194 (2017).
Nishio, J. et al. Use of a novel FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of alveolar rhabdomyosarcoma. Lab. Invest. 86, 547–556 (2006).
Missiaglia, E. et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J. Clin. Oncol. 30, 1670–1677 (2012). This paper highlights the development and testing of what seems to be a durable molecular biomarker for risk stratification in RMS.
Skapek, S. X. et al. PAX–FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children’s oncology group report. Pediatr. Blood Cancer 60, 1411–1417 (2013).
Rudzinski, E. R. et al. Myogenin, AP2beta, NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Am. J. Surg. Pathol. 38, 654–659 (2014).
Villani, A. et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li–Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol. 17, 1295–1305 (2016).
Kratz, C. P. et al. Cancer screening recommendations for individuals with Li–Fraumeni syndrome. Clin. Cancer Res. 23, e38–e45 (2017).
Malkin, D., Nichols, K. E., Schiffman, J. D., Plon, S. E. & Brodeur, G. M. The future of surveillance in the context of cancer predisposition: through the murky looking glass. Clin. Cancer Res. 23, e133–e137 (2017).
Phallen, J. et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci. Transl Med. 9, eaan2415 (2017).
Ferrari, A. et al. Adult-type soft tissue sarcomas in pediatric-age patients: experience at the Istituto Nazionale Tumori in Milan. J. Clin. Oncol. 23, 4021–4030 (2005).
Blakely, M. L. et al. Prognostic factors and surgical treatment guidelines for children with rhabdomyosarcoma of the perineum or anus: a report of Intergroup Rhabdomyosarcoma Studies I through IV, 1972 through 1997. J. Pediatr. Surg. 38, 347–353 (2003).
Crist, W. M. et al. Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee. J. Clin. Oncol. 8, 443–452 (1990).
Malempati, S. & Hawkins, D. S. Rhabdomyosarcoma: review of the Children’s Oncology Group (COG) soft-tissue sarcoma committee experience and rationale for current COG studies. Pediatr. Blood Cancer 59, 5–10 (2012).
Ferrari, A. et al. Access to clinical trials for adolescents with soft tissue sarcomas: enrollment in European pediatric soft tissue sarcoma study group (EpSSG) protocols. Pediatr. Blood Cancer 64, e26348 (2017).
Dantonello, T. M. et al. Survival following disease recurrence of primary localized alveolar rhabdomyosarcoma. Pediatr. Blood Cancer 60, 1267–1273 (2013).
Heyn, R. M. et al. The role of combined chemotherapy in the treatment of rhabdomyosarcoma in children. Cancer 34, 2128–2142 (1974).
Gallego, S. et al. Detection of bone marrow micrometastasis and microcirculating disease in rhabdomyosarcoma by a real-time RT-PCR assay. J. Cancer Res. Clin. Oncol. 132, 356–362 (2006).
Meza, J. L., Anderson, J., Pappo, A. S. & Meyer, W. H. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children’s Oncology Group. J. Clin. Oncol. 24, 3844–3851 (2006).
Lawrence, W. Jr, Anderson, J. R., Gehan, E. A. & Maurer, H. Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children’s Cancer Study Group. Pediatr. Oncol. Group. Cancer 80, 1165–1170 (1997).
Maurer, H. M. et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 61, 209–220 (1988).
Hingorani, P. et al. Clinical application of prognostic gene expression signature in fusion gene-negative rhabdomyosarcoma: a report from the Children’s Oncology Group. Clin. Cancer Res. 21, 4733–4739 (2015).
Bisogno, G. et al. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol. 19, 1061–1071 (2018).
Bisogno, G. et al. The role of doxorubicin in the treatment of rhabdomyosarcoma: preliminary results from the EpSSG RMS 2005 randomized trial. Pediatr. Blood Cancer 61, S133–S134 (2014).
Casanova, M. et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer 101, 1664–1671 (2004). This early report demonstrates the potential value of low-dose ‘maintenance’ chemotherapy — an emerging concept that provides a new opportunity to improve survival for those with the highest-risk disease.
Bisogno, G. et al. Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS): a report from the European paediatric soft tissue sarcoma study group (EpSSG). J. Clin. Oncol. https://doi.org/10.1200/JCO.2018.36.18_suppl.LBA2 (2018).
Pappo, A. S. et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children’s Oncology Group. J. Clin. Oncol. 25, 362–369 (2007).
Hawkins, D. et al. Vincristine, dactinomycin, cyclophosphamide (VAC) versus VAC/V plus irinotecan (VI) for intermediate-risk rhabdomyosarcoma (IRRMS): a report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. J. Clin. Oncol. 32, 10004 (2014).
Hawkins, D. S. et al. Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the Children’s Oncology Group. J. Clin. Oncol. 36, 2770–2777 (2018).
Bisogno, G. et al. Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma. Eur. J. Cancer 45, 3035–3041 (2009).
Weigel, B. J. et al. Intensive multiagent therapy, including dose-compressed cycles of ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide, irinotecan, and radiation, in patients with high-risk rhabdomyosarcoma: a report from the Children’s Oncology Group. J. Clin. Oncol. 34, 117–122 (2016).
Walterhouse, D. O. et al. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J. Clin. Oncol. 32, 3547–3552 (2014).
Walterhouse, D. O. et al. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Cancer 123, 2368–2375 (2017).
Dasgupta, R., Fuchs, J. & Rodeberg, D. Rhabdomyosarcoma. Semin. Pediatr. Surg. 25, 276–283 (2016).
Kieran, K. & Shnorhavorian, M. Current standards of care in bladder and prostate rhabdomyosarcoma. Urol. Oncol. 34, 93–102 (2016).
Maurer, H. M. et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 71, 1904–1922 (1993).
Terezakis, S. A. & Wharam, M. D. Radiotherapy for rhabdomyosarcoma: indications and outcome. Clin. Oncol. 25, 27–35 (2013).
Saltzman, A. F. & Cost, N. G. Current treatment of pediatric bladder and prostate rhabdomyosarcoma. Curr. Urol. Rep. 19, 11 (2018).
Casey, D. L. & Wolden, S. L. Rhabdomyosarcoma of the head and neck: a multimodal approach. J. Neurol. Surg. B 79, 58–64 (2018).
Ferrari, A. et al. Rhabdomyosarcoma in infants younger than one year old: a report from the Italian Cooperative Group. Cancer 97, 2597–2604 (2003).
Malempati, S. et al. Rhabdomyosarcoma in infants younger than 1 year: a report from the Children’s Oncology Group. Cancer 117, 3493–3501 (2011).
Alaggio, R. et al. A molecular study of pediatric spindle and sclerosing rhabdomyosarcoma: identification of novel and recurrent VGLL2-related fusions in infantile cases. Am. J. Surg. Pathol. 40, 224–235 (2016).
Pappo, A. S. et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J. Clin. Oncol. 17, 3487–3493 (1999).
Pappo, A. S. et al. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer 120, 2448–2456 (2014).
Kim, A. et al. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: a report from the Children’s Oncology Group. Pediatr. Blood Cancer 62, 1562–1566 (2015).
Wagner, L. M. et al. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children’s Oncology Group. Pediatr. Blood Cancer 62, 440–444 (2015).
Mascarenhas, L. et al. Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine (V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma (RMS): a report from the Children’s Oncology Group (COG). J. Clin. Oncol. 32, S10003 (2014).
Wolfe, J. et al. Symptoms and distress in children with advanced cancer: prospective patient-reported outcomes from the PediQUEST study. J. Clin. Oncol. 33, 1928–1935 (2015).
Gupta, A. A. et al. Patterns of chemotherapy-induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma: a report from the Children’s Oncology Group. Pediatr. Blood Cancer 64, e26479 (2017).
Cotter, S. E. et al. Proton radiotherapy for pediatric bladder/prostate rhabdomyosarcoma: clinical outcomes and dosimetry compared to intensity-modulated radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 81, 1367–1373 (2011).
Macedo, A. Jr et al. Sexual function in teenagers after multimodal treatment of pelvic rhabdomyosarcoma: a preliminary report. J. Pediatr. Urol. 6, 605–608 (2010).
Frees, S. et al. Erectile function after treatment for rhabdomyosarcoma of prostate and bladder. J. Pediatr. Urol. 12, 404.e1–404.e6 (2016).
Martelli, H. et al. Quality of life and functional outcome of male patients with bladder–prostate rhabdomyosarcoma treated with conservative surgery and brachytherapy during childhood. Brachytherapy 15, 306–311 (2016).
Raney, B. et al. Late effects in 164 patients with rhabdomyosarcoma of the bladder/prostate region: a report from the international workshop. J. Urol. 176, 2190–2194; discussion 2194–2195 (2006).
Shapiro, D. D., Harel, M., Ferrer, F. & McKenna, P. H. Focusing on organ preservation and function: paradigm shifts in the treatment of pediatric genitourinary rhabdomyosarcoma. Int. Urol. Nephrol. 48, 1009–1013 (2016).
Rodeberg, D. A. et al. Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: a report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. Int. J. Cancer 137, 204–211 (2015).
Chen, S. et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160, 1246–1260 (2015).
Stewart, E. et al. Orthotopic patient-derived xenografts of paediatric solid tumours. Nature 549, 96–100 (2017).
Langenau, D. M. et al. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev. 21, 1382–1395 (2007).
Amatruda, J. F., Shepard, J. L., Stern, H. M. & Zon, L. I. Zebrafish as a cancer model system. Cancer Cell 1, 229–231 (2002).
Galindo, R. L., Allport, J. A. & Olson, E. N. A. Drosophila model of the rhabdomyosarcoma initiator PAX7–FKHR. Proc. Natl Acad. Sci. USA 103, 13439–13444 (2006).
Linardic, C. M. & Counter, C. M. Genetic modeling of Ras-induced human rhabdomyosarcoma. Methods Enzymol. 438, 419–427 (2008).
Linardic, C. M., Downie, D. L., Qualman, S., Bentley, R. C. & Counter, C. M. Genetic modeling of human rhabdomyosarcoma. Cancer Res. 65, 4490–4495 (2005).
Sharp, R. et al. Synergism between Ink4a/Arf inactivation and aberrrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat. Med. 8, 1276–1280 (2002).
Merchant, M. S. et al. Adjuvant immunotherapy to improve outcome in high-risk pediatric sarcomas. Clin. Cancer Res. 22, 3182–3191 (2016).
Merchant, M. S. et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin. Cancer Res. 22, 1364–1370 (2016).
Chicas-Sett, R., Morales-Orue, I., Rodriguez-Abreu, D. & Lara-Jimenez, P. Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: a systematic review. Clin. Transl Radiat. Oncol. 9, 5–11 (2018).
Allen, C. E. et al. Target and agent prioritization for the Children’s Oncology Group-National Cancer Institute pediatric MATCH trial. J. Natl Cancer Inst. 109, djw274 (2017).
Volchenboum, S. L. et al. Data commons to support pediatric cancer research. Am. Soc. Clin. Oncol. Educ. Book 37, 746–752 (2017).
Ren, Y. X. et al. Mouse mesenchymal stem cells expressing PAX–FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res. 68, 6587–6597 (2008).
Hahn, H. et al. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat. Med. 4, 619–622 (1998).
Hatley, M. E. et al. A mouse model of rhabdomyosarcoma originating from the adipocyte lineage. Cancer Cell 22, 536–546 (2012).
Nyagetuba, J. K. M. & Hansen, E. N. Pediatric solid tumors in Africa: different biology? Curr. Opin. Pediatr. 29, 354–357 (2017).
Gupta, S. et al. in Cancer: Disease Control Priorities 3rd edn Vol. 3 Ch. 3 (eds Gelband, H., Jha, P., Sankaranarayanan, R. & Horton, S.) 121–146 (World Bank, 2015).
Antillon, F. et al. Treating pediatric soft tissue sarcomas in a country with limited resources: the experience of the Unidad Nacional de Oncologia Pediatrica in Guatemala. Pediatr. Blood Cancer 51, 760–764 (2008).
Sultan, I., Qaddoumi, I., Yaser, S., Rodriguez-Galindo, C. & Ferrari, A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J. Clin. Oncol. 27, 3391–3397 (2009).
Ferrari, A. et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer 98, 571–580 (2003).
Davis, L. E. et al. Clinical trial enrollment of adolescents and young adults with sarcoma. Cancer 123, 3434–3440 (2017).
Helman, L. J., Wexler, L. H. & Meyer, W. H. in Principles and Practice of Pediatric Oncology (eds Pizzo, P. A. & Poplack, D. G.) 798–826 (Wolters Kluwer, Philadelphia, PA, 2016).
Grufferman, S. et al. Parental military service, agent orange exposure, and the risk of rhabdomyosarcoma in offspring. J. Pediatr. 165, 1216–1221 (2014).
Nature Reviews Disease Primers thanks P.-L. Lollini, B. Schäfer, T. Triche and the other anonymous referee(s) for the peer review of this work.
All authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Skapek, S.X., Ferrari, A., Gupta, A.A. et al. Rhabdomyosarcoma. Nat Rev Dis Primers 5, 1 (2019). https://doi.org/10.1038/s41572-018-0051-2
Journal of Translational Medicine (2022)
Enhancer promoter interactome and Mendelian randomization identify network of druggable vascular genes in coronary artery disease
Human Genomics (2022)
Model-based inference of metastatic seeding rates in de novo metastatic breast cancer reveals the impact of secondary seeding and molecular subtype
Scientific Reports (2022)
Signal Transduction and Targeted Therapy (2022)
Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma
npj Precision Oncology (2022)